Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Frontdoor Inc (Symbol: FTDR), where a total of 2,600 contracts have traded so far, ...

Arcturus Therapeutics' ARCT-032 gene therapy for cystic fibrosis has been designated as an "orphan drug" in the U.S. and Europe. The therapy has the potential to generate significant revenues, similar ...

ARCTURUS THERAPEUTICS ($ARCT) posted quarterly earnings results on Monday, May 12th. The company reported earnings of -$0.52 per share, beating estimates of -$1.36 by ...

Arcturus Therapeutics (ARCT) closed the last trading session at $10.84, gaining 5.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Arcturus Therapeutics (NASDAQ:ARCT) traded sharply lower on Friday after the company announced detailed results from a Phase 1b trial for ARCT-032, an experimental therapy for the lung disorder cystic ...

Arcturus Therapeutics Holdings Inc ARCT shares are trading higher Wednesday after the company reported strong fourth-quarter results and provided an update on pipeline progress. Guggenheim reiterated ...

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stands ...

ARCT-810 could reduce the need for ammonia scavengers and ease the rigid dietary protein restrictions that OTC patients face today, thus improving the quality of life for those with the disease.

Full cohort data from the ARCT-154 (5 mcg) arm of the ongoing Phase 1/2 booster study shows 30-fold increase in neutralizing antibody geometric mean concentrations against SARS-CoV-2 at Day 15 ...